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104 The Journal of Thoracic and CardioObjective: The Cox maze procedure was introduced in 1987 for the treatment of atrial
fibrillation. This study evaluated the predictors of late atrial fibrillation recurrence in 276
consecutive patients who underwent this procedure at our institution.
Methods: From 1987 through June 2003, 276 patients (79 female and 197 male
patients; mean age, 55 11 years) underwent the Cox maze procedure. Thirty-three
patients had Cox maze procedure I, 16 patients had Cox maze procedure II, and 197
patients had Cox maze procedure III. The last 30 patients underwent a modified
procedure (Cox maze procedure IV) with bipolar radiofrequency ablation. There
were 113 (41%) patients who had a concomitant operation, most commonly either
a mitral valve procedure (19%) or coronary artery bypass grafting (20%). Data were
analyzed by means of univariate analysis, with preoperative and perioperative
variables used as covariates. Patient follow-up was conducted by means of ques-
tionnaire, physician examination, and electrocardiographic documentation. All pa-
tients had a minimum of 6 months of follow-up.
Results: Patient follow-up was achieved in 92.8% of cases, with a mean follow-up
time of 5.8  3.6 years. Risk factors for late atrial fibrillation recurrence were
duration of preoperative atrial fibrillation (P .01) and Cox maze procedure version
(P  .001). There was no difference in actuarial 10-year survival between the Cox
maze procedure versions.
Conclusion: The Cox maze procedure remains the gold standard for the treatment of
atrial fibrillation and has excellent long-term efficacy. The most significant predictor
of late recurrence was duration of preoperative atrial fibrillation, suggesting that
earlier surgical intervention would further increase efficacy.
The Cox maze procedure (CMP) was first performed by James L. Coxin 1987. Since then, there have been 4 iterations of this operation.1The long-term success rates of this procedure at our institution havebeen in excess of 90%.2 The CMP I was effective in eliminatingatrial fibrillation (AF) but was discontinued because of the highincidence of chronotropic incompetence and the perceived high rate
of pacemaker implantation. The CMP II had similar problems and was also tech-
nically difficult because it required transection of the superior vena cava.3 Because
of the shortcomings of these 2 original versions, the CMP III was introduced and
remained the gold standard for the treatment of AF for more than a decade.4
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CMP III was simplified by replacing many of the traditional
cut-and-sew lesions with linear lines of ablation by using a
bipolar radiofrequency energy device (Atricure, Inc, Cin-
cinnati, Ohio).5-7 This new version was first performed in
2002 and has been termed the CMP IV. This procedure
differs considerably from the CMP III because it isolates the
right and left pulmonary veins as 2 islands (Figure 1). It
preserves the right atrial appendage and leaves most of the
posterior left atrium in electrical continuity with the remain-
der of the atrium.
Although the CMP was initially introduced as a lone
procedure, it has evolved to the current practice in which it
is commonly incorporated with other cardiac procedures,
such as valvular and coronary artery bypass surgeries. The
efficacy and safety of such concomitant procedures has been
reported by our group and others throughout the world.8-11
Although the CMP has enjoyed significant clinical success,
there have been few reports of factors leading to late recur-
rence of AF.12,13 Despite the fact that our institution has had
the world’s longest experience with the CMP and its differ-
ent iterations, we have not previously examined this issue.
In this study our prospective database was reviewed to
evaluate the predictors of late AF recurrence in 276 con-
secutive patients who underwent a CMP at Barnes-Jewish
Hospital.
Methods and Patients
From September 1987 through June 2003, 276 patients underwent
a CMP. The procedures were performed through a median ster-
notomy on cardiopulmonary bypass with an arrested heart. Thirty-
three patients had a CMP I, 16 patients had a CMP II, 197 patients
had a CMP III, and 30 patients had a CMP IV. There were 113
(41%) patients who underwent a concomitant cardiac operation,
Figure 1. Bipolar radiofrequency–modified CMP IV. LAA, Left
atrial appendage; RAA, right atrial appendage; SVC, superior vena
cava; IVC, inferior vena cava; RF, radiofrequency.with the most common being either a mitral valve procedure or
The Journal of Thoracicoronary artery bypass grafting (Table 1). The number of patients
having concomitant procedures increased over time, with an inci-
dence of 19% for CMP I, 12% for the CMP II, 54% for the CMP
III, and 67% for the CMP IV.
In this series patients presenting with intermittent AF were
defined as having paroxysmal AF. Those presenting with contin-
uous AF were defined as having persistent AF. The patients’
clinical profiles and postoperative outcomes were recorded pro-
spectively. More than 400 variables were collected on each patient.
The following were considered major perioperative complications:
reoperation for bleeding, renal failure requiring dialysis, medias-
tinitis, placement of an intra-aortic balloon pump, and periopera-
tive transient ischemic attack or stroke. The incidence of early
postoperative permanent pacemaker placement (within 30 days of
the procedure) was documented. An early postoperative tachyar-
rhythmia was defined as occurring within the first 30 days and
included AF, atrial flutter, and other supraventricular tachycardias.
Patient follow-up was conducted by mailed questionnaire or
telephone interview. All patients complaining of AF or those
taking warfarin or antiarrhythmic drug therapy had a review of
both the referring cardiologist’s office charts and a recent electro-
cardiogram (ECG). A patient was considered to have recurrent AF
if they had either self-reported AF episodes or ECG-documented
arrhythmias. Late recurrence of AF was defined as recurrent AF–
atrial flutter occurring at least 6 months after the operation. All
deaths occurring outside of the hospital were confirmed by con-
tacting the patient’s relatives, the patient’s physician, and/or
county death records.
Thirteen preoperative and perioperative variables were evalu-
ated in a univariate analysis to identify potential predictors of late
AF recurrence. These included age, sex, indication for surgical
intervention, type and duration of AF, CMP version, surgical
procedure, aortic crossclamp time, cardiopulmonary bypass time,
perioperative complications, early atrial tachyarrhythmias, and
pacemaker placement. This study was approved by the Washing-
ton University School of Medicine Institutional Review Board.
Informed consent and permission for release of information were
obtained from each participant.
Data were collected and managed in Microsoft Access 2000
and analyzed with SPSS 11.0 software (SPSS, Inc, Chicago, Ill).
Normally distributed continuous data were expressed as means 
TABLE 1. Concomitant cardiac procedures
n  113 %
Mitral valve procedure only 33 29
CABG only 40 35
Mitral valve procedure/CABG 12 10
Aortic valve procedure/CABG 2 2
Tricuspid valve procedure only 1 1
Double-valve procedure 3 3
Double-valve procedure/CABG 2 2
Other procedures* 20 18
CABG, Coronary artery bypass grafting.
*Other procedures include atrial septal defect closure, septal myectomy,
myxoma resection, and repair of pectus excavatum.SD unless otherwise specified. Nonnormally distributed continu-
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Q75). Univariate analyses were performed for all relevant cate-
goric variables by means of 2 analysis and t tests or the Mann-
Whitney U test for continuous variables. One-way analysis of
variance was used for more than 2 group comparisons. Univariate
Cox regression was used to determine which covariates were
predictors of late recurrence of AF or survival. Kaplan-Meier
estimates were used to depict freedom from AF and long-term
survival. Cox regression analyses were performed by using either
duration of preoperative AF or CMP version as covariates to depict
their effect on late recurrence of AF (Figures 2 and 3).
Results
Demographics
The mean age of our patients undergoing the CMP proce-
dure was 54.9  11.4 years (range, 20-80 years; Table 2).
There were 197 men and 79 women. Fifty-eight percent of
patients were given diagnoses of paroxysmal AF at the time
of the operation, with the remainder having persistent AF.
The mean duration of AF was 8.2  7.7 years, with a range
of 2 months to 46 years. The median duration of AF in our
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Figure 2. Freedom from late AF recurrence by CMP version.
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Figure 3. Freedom from late AF recurrence by duration of preop-
erative AF.series was 5 years. There was no significant difference in the
106 The Journal of Thoracic and Cardiovascular Surgery ● Janumean preoperative AF duration by CMP version (P  .18).
The indications for surgical intervention were arrhythmia or
drug intolerance in 83.3% (230/276) of patients and cere-
brovascular event in 16.7% (46/276) of patients.
Perioperative Results
The mean aortic crossclamp time for the entire group was
96  34 minutes (84  27 minutes for a lone CMP and 114
 36 minutes for concomitant procedures). The mean car-
diopulmonary bypass time for all patients was 183  44
minutes (169  38 minutes for a lone CMP and 203  45
minutes for concomitant procedures). The median intensive
care unit stay was 2 days. The median hospital length of stay
was 11 days. Thirteen percent (37/276) of patients had a
major perioperative complication. These complications in-
cluded reoperation for bleeding in 19 patients, intra-aortic
balloon pump placement in 12 patients, renal failure in 5
patients, stroke in 4 patients, and mediastinitis in 4 patients.
Six patients experienced more than one major perioperative
complication. The 30-day operative mortality rate was 1.4%
(4/276).
Early postoperative atrial tachyarrhythmias were docu-
mented in 44.6% (123/276) of patients. These postoperative
dysrhythmias were usually transient, and 97% resolved by
the 21st postoperative day.14 Early permanent pacemaker
placement within 30 days of the operation was required in
16.7% (46/276) of patients. The majority of these patients
(78%) had documented evidence of sick sinus syndrome
preoperatively. There was no significant difference in the
incidence of postoperative pacemaker implantation between
the CMP versions (P  .16).
Late Follow-up
Late follow-up was achieved in 92.8% (256/276) of pa-
TABLE 2. Patient characteristics
n  276 %
Age (y) 54.9  11.4
Male sex 197 71
Paroxysmal AF 159 58
AF duration (y)
Mean 8.2  7.7
Median 5 (IQR, 3-10)
AF cause
Lone AF 179 65
Valvular disease 41 15
Coronary artery disease 56 20
Indications for surgical intervention
Arrhythmia intolerance 196 71
Drug failure 34 12
Cerebrovascular event 46 17
AF, Atrial fibrillation; IQR, interquartile range.tients, with a mean follow-up duration 6.0  3.6 years. The
ary 2005
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years). The mean follow-up for the CMP I, CMP II, CMP
III, and CMP IV groups was 13.7, 9.6, 9.6, and 1.1 years,
respectively.
Recurrence of AF
In our analysis of AF recurrence, all patients identifying
themselves as being in AF had confirmation by their cardi-
ologist and an ECG or Holter recording documentation
when possible. Late AF recurrence had occurred in 7.8%
(20/256) at last follow-up. Of the patients in sinus rhythm,
19.5% were taking antiarrhythmic drugs at last follow-up.
Six patients required a catheter ablation for either atypical
atrial flutter or focal atrial tachycardia during the follow-up
period. A univariate analysis identified duration of preop-
erative AF (P  .013) and CMP version (P  .001) as the
only significant predictors of late AF recurrence (Table 3).
Patients with a preoperative cerebrovascular event exhibited
a trend toward higher recurrence rates of AF (P  .054).
There was a significant difference in the freedom from
AF recurrence over time between CMP versions I, II, and III
(P  .03, Figure 2). The CMP III had a success rate of
89.3% at 10 years. In contrast, the CMP I and CMP II were
associated with a late freedom from AF recurrence of 75.4%
and 83.6%, respectively. The overall freedom from AF for
our entire experience was 92.2%. Patients undergoing the
CMP IV had a success rate of 93.1% at 6 months, but
follow-up was too short to allow comparison with previous
versions.
Duration of preoperative AF was also a significant pre-
dictor. Patients presenting with a preoperative AF duration
of 5 years had a 91.1% freedom from recurrence at 10 years
after the CMP. Comparatively, those patients with a preop-
erative AF duration of 20 years had only a 72.3% freedom
TABLE 3. Univariate analysis of patients with late AF recu
Late AF recurrenc
(%), n  20
Demographics
Age (y) 59.2  10.
Male sex 13 (65.0)
Paroxysmal AF 8 (40.0)
AF duration (y) 16.2  13.7, 10 (IQ
CMP version
Preoperative CV event 7 (35.0)
Perioperative results
Major perioperative complications 5 (25.0)
Hospital LOS (d) 12 (IQR, 8-2
Early atrial tachyarrhythmias 13 (65.0)
Early permanent pacemaker 3 (15.0)
AF, Atrial fibrillation; IQR, interquartile range; CMP, Cox maze procedure;from late AF recurrence (Figure 3).
The Journal of ThoraciThere were no other significant predictors of recurrence
among the demographic data, including patient age, sex, or
type of AF. Perioperative variables, including surgical pro-
cedure (lone CMP vs concomitant procedure), aortic cross-
clamp time, and cardiopulmonary bypass time, were ana-
lyzed by using univariate analysis but were not found to be
significant predictors of late AF recurrence.
Patient Survival
The overall survival was 88.7% at last follow-up. There was
no significant difference in actuarial 10-year survival be-
tween the various groups. The estimated 10-year survival
rates for the CMP I, CMP II, and CMP III groups were 92%,
93%, and 94%, respectively. At last follow-up, patient sur-
vival in the CMP IV group was 93.3%.
Discussion
The CMP has evolved to become the most successful sur-
gical treatment for AF.9,10,15,16 Our institution has had the
longest experience with the CMP and has maintained a
prospective database of our results. Although we have pub-
lished extensively on our series, this is the first time we have
evaluated our database for predictors of late AF recurrence.
In this study, the significant predictors of late recurrence of
AF by univariate analysis were duration of preoperative AF
and CMP version.
There has been no previous comparative analysis of late
results between the various modifications of the CMP. In
this study, there was no significant difference in either
operative or late mortality among the 4 different versions of
the CMP. There was a larger percentage of patients under-
going concomitant procedures in the CMP III and IV groups
when compared with the CMP I and CMP II groups. This is
to be expected because the procedure was first applied for
ce and those free from AF recurrence
up Freedom from late AF group
(%), n  236 P value
55.1  11.3 .11
169 (71.6) .61
139 (58.9) .16




11.0 (IQR, 8-16) .17
105 (44.5) .10
41 (17.4) 1.0




1)the treatment of lone AF. Over the years, the CMP has been
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with proven efficacy and low mortality.2,15,16 By using a
univariate analysis, the CMP I and II groups had a signifi-
cantly lower success rate than the CMP III group. The CMP
IV group had a freedom from AF of 93.3%, but follow-up
was too limited to allow a valid comparison with earlier
versions.
The reasons for the higher failure rate for the CMP I and
II groups are unknown. All 3 procedures had similarly
extensive surgical incisions in both atria, and thus it is hard
to implicate a specific technical factor. It is possible that
there were a greater number of patients in the early versions
with untreated sinus node dysfunction who did not receive
a permanent pacemaker. These patients might have had a
higher incidence of premature atrial contractions, which
could serve as a trigger for atrial tachyarrhythmias.17 An-
other contributing factor might have been a trend (P  .18)
toward a longer preoperative AF duration in the CMP I
group (10.6  9.7 years) compared with the later the CMP
III (8.1  7.5) and CMP IV (7.4  7.5 years) version.
Preoperative AF duration was also shown to be a signif-
icant predictor of late failure. Other investigators have iden-
tified duration of preoperative AF as a predictor of late
recurrence after the CMP.18-21 Interestingly, patients with
AF duration of 5 years had an estimated 91.1% freedom
from AF at 10 years. This decreased precipitously to 72.3%
for those patients with an AF duration of 20 years. Pro-
longed AF has been shown to result in electrical remodel-
ing, atrial dilatation, loss of atrial muscle mass, and fibrotic
changes occurring within the atrial myocardium.22-25 This
might be one of the explanations for the higher failure rate.
These data would suggest that the earlier referral of patients
for CMP would lead to improved surgical results.
A final interesting finding was the trend (P  .054)
toward higher recurrence of AF in patients with a preoper-
ative cerebrovascular event. It is difficult to explain this
finding unless there was some associated dysfunction of the
autonomic nervous system in these patients. There also
might have been confounding covariates that unduly influ-
enced our univariate analysis.
This study had several limitations. One of the major
problems was the reliance on the patient’s history, referring
physician records, and ECGs to determine their rhythm
during the follow-up period. Patients who stated that they
were in sinus rhythm did not have ECG follow-up. This
might have resulted in an underestimation of AF recurrence.
However, all of these patients had a previous history of AF,
and most were sensitive to their arrhythmia symptomatol-
ogy. Our follow-up should have captured the majority of
treatment failures. It is also possible that patients counted as
failures were not actually in AF. It was not possible to
obtain ECG confirmation of the arrhythmia in 8 (40.0%) of
the 20 failures. Unfortunately, because most of these pa-
108 The Journal of Thoracic and Cardiovascular Surgery ● Janutients were from outside our region, complete and thorough
follow-up was not always possible. Ideally, Holter monitor-
ing of all patients would have been preferred at regular
intervals in the postoperative period. However, to our
knowledge, these data have never been gathered at any
center because of their expense and impracticality.
In our data analysis a univariate model was chosen in
preference of a multivariate model because the incidence of
AF recurrence was low. This is clearly a limitation; how-
ever, it would not be statistically valid to use a multivariate
analysis with our relatively small number of treatment fail-
ures.
Other investigators have shown that left atrial dimen-
sions (left atrial diameter 65 mm) and AF wave (1.0
mm) have been associated with late AF recurrence.13,20 In
this study documentation of left atrial dimension was avail-
able in less than one quarter of our patients. This was due to
the fact that when the CMP was first introduced, it was not
common practice to quantitatively record left atrial dimen-
sions nor was there a standardized method to measure this
variable. Similarly, there were no detailed ECG analyses of
preoperative atrial activity in these patients. This prevented
us from examining their predictive values in this retrospec-
tive analysis.
Finally, it was difficult to assess the efficacy of the CMP
IV in comparison with the previous CMP versions because
the follow-up period was much shorter. Although early
results are encouraging, further follow-up will be required
to assess long-term efficacy.
In summary, the CMP remains the gold standard for the
surgical treatment of AF and has evolved over time into a
procedure with excellent long-term efficacy. Preoperative
AF duration and CMP version were the only predictors of
late recurrence in our database. Our data suggest that an
early referral of patients with medically refractory AF for
curative surgical therapy would increase the long-term suc-
cess rates.
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Discussion
Dr A. Marc Gillinov (Cleveland, Ohio). That was an excellent
presentation of very important data from Washington University in
St Louis. This is a large experience, nearly 300 patients spanning
16 years. That makes this the longest follow-up of any contempo-
rary surgical or ablative approach to the treatment of AF. The
patients might not be entirely representative of those we see in the
operating room today, with a preponderance of lone AF and
paroxysmal AF in this series.
The Journal of ThoraciIn a courageous maneuver that is uncommon, the investigators
chose to analyze failures. In fact, to their credit, there were only 20
failures in the entire series, and this precluded a multivariable
analysis. Still, though, they came up with 2 very important mes-
sages: what we do in the operating room for lesion set matters, and
the duration of preoperative AF also matters. These are 2 modifi-
able factors, factors that we can deal with. I think the data stand for
themselves, and I have 3 questions that ask the authors to speculate
as to their importance for our future practice.
First, with your experience encompassing 4 different proce-
dures, should different patients with different types of AF have
different operations? For example, should paroxysmal AF or con-
tinuous AF be treated differently one from the other?
Dr Damiano. Thank you, Dr Gillanov, for your kind com-
ments, and I certainly would like to start by recognizing your
important contributions in this area.
I think that is an excellent question, and these data really do
not address whether different procedures or possibly more
limited procedures might or might not be successful in certain
patients. I think the one thing you can take from this series is
that with the full lesion set of a CMP III or a CMP IV—and
basically all the procedures had very similar lesion sets—that
you can get excellent late results. Interestingly, we had no
difference in late success, irrespective of whether you had
paroxysmal or continuous AF, and this is in distinct contradis-
tinction to the earlier results with catheter-based pulmonary
vein isolation.
I think what I would take home from this study is that clearly
it is important how long patients are in AF before they are referred
to us, and it would certainly suggest that in these patients there is
irreversible electrical and anatomic remodeling going on in the
atria that, despite this procedure, really prevent long-term success.
It is my belief and that of our group that it is very important to
communicate this to the cardiologists and that early referral of
patients for surgical correction, whether with perhaps a more
limited procedure or this procedure, will clearly improve our
results. I think if we can get early referral, we might be able to take
a more limited approach in certain patients.
Dr Gillinov. My second question concerns the CMP IV. The
CMP III has a box lesion around all 4 pulmonary veins, and the
CMP IV has 3 sides of the box, and therefore more of the left
atrium is in electrical and physical continuity. Is this important?
Dr Damiano. That is an excellent question. Again, I am not
sure our data could answer that. I think it is important when you
look at this study to remember that the median follow-up in the
CMP IV group is only 1.1 years, as opposed to more than 10
years, for instance, in the CMP I group. Thus I think it is a little
early to speculate on whether leaving that posterior left atrium
in continuity is going to have a positive or a potentially negative
late effect on our results, and we are certainly closely continu-
ing to follow that. I would only say that our early results are
encouraging that this, which is a quite simpler version of the
procedure, has similar short-term efficacy, and we will just have
to wait and see whether that is going to hold up in the long term.
Your point is an excellent one, and the one thing we have
noticed right away is that the occurrence of earlier atrial tachy-
arrhythmias is significantly higher in the CMP IV group when
compared with the CMP III group, slightly more than 60%
c and Cardiovascular Surgery ● Volume 129, Number 1 109
Surgery for Acquired Cardiovascular Disease Gaynor et al
A
CDcompared with approximately 40% in the CMP III. Therefore
this might be due to the fact that we are leaving a lot more
atrium in electrical continuity. But interestingly, as this study
shows, early atrial tachyarrhythmias, which I think is actually
an important point, do not seem to be a significant predictor of
late failure.
Dr Gillinov. My final question concerns the right atrial lesions.
Most people would say that AF usually comes from the left atrium.
Do you believe the right atrial lesions are important for fibrillation
or perhaps for flutter?
Dr Damiano. Yes, certainly I think many people are omitting
the right atrial lesions, and unfortunately, I would only say that
at least in these data, all of the patients in this study had
right-sided lesions, and I cannot really comment what the
efficacy would be if you left them out. I would say that we have
done—and it is a very unrepresentative group but I will give
you this anecdotal experience—12 patients in whom we have
just done either left-sided lesions or pulmonary vein isolation
alone and a left atrial appendectomy, and we saw a postopera-
tive incidence of atrial flutter in that group of approximately
25%. Other experiences around the world—and there are a
number of investigators in this room and attending this meeting
who have had extensive experience—would indicate perhaps a
10% to 15% incidence of late atrial flutter.
Interestingly, we recently have gone back and analyzed some of
our mapping data on human AF that was referred. We looked at
approximately 21 patients evenly split between paroxysmal and
continuous AF, and a third of those patients had their driver focus
of the AF in the right side. Therefore theoretically, if we had not
done right-sided lesions, this might have been a group of patients
that would have experienced failures.
In my opinion there will be a higher failure rate without the
right-sided lesions. I think there are clearly a significant number of
patients who have left-sided AF. The problem is we are just not
smart enough to identify who those are right now.
Dr Joao Q. Melo (Carnaxide, Portugal). Good article, Ralph.
My comment is that we all know that paroxysmal AF and persis-
tent AF are precursors for permanent AF, and it is the first article
in my life in which I can see where paroxysmal AF is not a
predictor of a good outcome. And you are also asking and pro-
posing earlier referral, and it is difficult to propose earlier referral
if paroxysmal AF is not a predictor of a good outcome. Therefore
my question is as follows: can you elaborate on why you found
paroxysmal AF not being a predictor of a good outcome, and can
that be related with patient selection because that is the only reason
I can find for such a finding?
Dr Damiano. Actually, it is an excellent question, and when
we look back on our previous study we presented when we just
analyzed the CMP III experience, we did not find paroxysmal AF
to be a risk factor. Now I think perhaps one difference between our
study and others is that all these patients had very extensive lesion
sets. With a limited lesion set or a catheter-based approach, I
would agree that if you are going to direct most of your attention
to the left side, you probably will see differences between parox-
ysmal and continuous AF. But this is really our results, and we did
not see any difference. It does not really come close to being
significant, perhaps because we use such an extensive lesion set in
our experience at Washington University.
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compared with that of others is that our average duration of AF
is actually quite long because this goes back to span an expe-
rience that began when Jim Cox first introduced this operation,
and most of those patients had had extremely long-lasting AF.
But I do not think that just because we did not show that
paroxysmal AF had better results than continuous AF that this
should discourage the cardiologists from referring patients ear-
lier.
We have had patients with very long-standing paroxysmal AF
in this study, and I think it does show that if you are having AF that
you are undergoing probably some type of an irreversible remod-
eling process and that despite what you do there are some patients
who we will not be able to cure. I think it is a message we have to
get across to the cardiology community.
Dr Yaron Moshkovitz (Tel-Aviv, Israel). I would like to ask
you whether you have got any information regarding the percent-
age of patients who seem to be in normal sinus rhythm after their
operations but in whom the atria still do not contract.
Dr Damiano. That is a very interesting question and continuing
to be an important point in the literature when evaluating a surgical
series treating AF. The answer to that is we simply do not have
data on atrial contractility in this large series.
You noticed we did not present any left atrial size data,
which also has been shown to be a strong predictor of failure by
Dr Kosakai and others around the world, and we simply did not
have adequate left atrial dimensions in all these patients. Our
group has previously published that there was impaired atrial
contractility in a subgroup of these patients in about 30% to
40% of the patients.
I would say we have gone back and looked at that, and the
reality is that the great majority of atrial emptying occurs pas-
sively, and whether your atria move has very little to add to your
atrial ejection fraction. We are looking at this in the laboratory
right now with magnetic resonance imaging. As long as you have
normal ventricular compliance, more than 80% of atrial emptying
occurs passively with opening of the mitral valve; you do not need
an atrial kick. And I would say in this series we only had one late
stroke, which would go along with the Cleveland Clinic experience
and others. This procedure does eliminate late stroke.
Most of the patients, more than 80%, are off any anticoagula-
tion, and I would argue that whatever their atrial contractility is, it
seems to be good enough.
Dr Guo-Wei He (Hong Kong, China). Dr Damiano, I enjoyed
your study very much. I work in both the United States and China.
Most of the patients with AF we encounter in China are associated
with rheumatic heart disease. Therefore I am particularly interested
in the cause’s effect on the long-term recurrence after the maze
procedure with mitral valve disease.
I realize that in your series you have 41 patients with heart
valve disease, probably too small a number to further divide into
subgroups according to the cause of the valve disease, such as
rheumatic or degenerative disease. However, I still would be very
interested to know whether there is a trend for those with rheu-
matic heart disease and severe mitral stenosis associated with AF
for long-standing history. Do they have a higher incidence to have
recurrence for AF or a lower incidence?
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exactly correct to point out that we do not have enough patients
with these problems to probably comment intelligently about
that precise risk factor for recurrence. All I can tell you is that
in our series the cause of AF was not a risk factor at all for lateThe Journal of Thoracidid not have as many patients with rheumatic disease as they
have seen in Japan and that obviously you see in China. There-
fore we really do not have the data set.
Again, referring back to some beautiful work that has been
done in Japan, clearly the large left atrium has a higher rate ofA
CDrecurrence. Now you have to remember that until recently we recurrence and late failure.c and Cardiovascular Surgery ● Volume 129, Number 1 111
